Clinic
Methodist Hospitals of Dallas
Methodist Hospitals of Dallas was paid $2.35M by Medicaid between Apr 2021 and Dec 2024, across 41 billing codes. Its largest line is 99283, emergency room visit (moderate) — 48% of everything it billed.
33Billing provider infoMETHODIST HOSPITALS OF DALLAS
MIDLOTHIAN, TX 76065
MIDLOTHIAN, TX 76065
33aNPI1487271375assigned 06/26/2020
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$2.35M
24GClaims27,795
24DCodes billed41
24AFirst – last monthApr 2021 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#110 of 320
Median peer was paid$205K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 2,720 | $150K | |
| 2022 | 7,916 | $604K | |
| 2023 | 11,218 | $1.11M | |
| 2024incomplete | 5,941 | $487K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 48% | 5,669 | 5,315 | $1.12M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 1,363 | 1,260 | $689K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5.4% | 1,737 | 1,608 | $128K |
| 80053 | Comprehensive metabolic panel | 3.2% | 2,237 | 1,869 | $74K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 640 | 568 | $65K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 1,249 | 1,190 | $53K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 2,820 | 2,301 | $42K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 1,460 | 1,341 | $28K |
| 87430 | 1.2% | 688 | 663 | $28K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 532 | 495 | $21K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 264 | 252 | $15K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 223 | 208 | $14K |
29 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 729 | $14K |
| 81001 | <1% | 1,197 | $11K | |
| 87081 | <1% | 416 | $7K | |
| 84703 | <1% | 1,079 | $7K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 41 | $5K |
| 87807 | <1% | 81 | $5K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 105 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 307 | $4K |
| 83690 | <1% | 845 | $4K | |
| 84484 | <1% | 500 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 214 | $2K |
| 99285 | Emergency room visit (most serious) | <1% | 13 | $1K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 367 | $1K |
| 84702 | <1% | 114 | $1K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12 | $589.92 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 609 | $542.21 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 700 | $405.94 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 446 | $375.18 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 526 | $354.09 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 72 | $329.20 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 148 | $264.16 |
| 81003 | <1% | 140 | $263.64 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 29 | $212.74 |
| 83880 | <1% | 17 | $98.94 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 54 | $36.62 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 83 | $36.61 |
| 86901 | <1% | 28 | $35.64 | |
| 86900 | <1% | 28 | $35.64 | |
| 83735 | <1% | 13 | $16.99 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBJERKE, CRAIG (EXECUTIVE VP & CFO)
| Provider | Location | Paid |
|---|---|---|
| Methodist Hospitals of Dallas | Dallas, TX | $13.18M |
| Methodist Hospitals of Dallas | Dallas, TX | $12.59M |
| Methodist Hospitals of Dallas | Mansfield, TX | $3.20M |
| Methodist Hospitals of Dallas | Richardson, TX | $2.65M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.